BioRx - Cincinnati, OH 45242 BioRx - Hemophilia, Infusion Suite Management, Home IVIG
BioRx - Hemophilia, Infusion Suite Management, Home IVIG

Home
About Us
BioRx News
Contact Us
Careers
Join Our List
 
10828 Kenwood Rd
Cincinnati, OH 45242
Phone: 866-442-4679
Fax: 877-588-8470

NHIA

BioRx News

BioRx Announces Health Outcomes Reporting Program for Primary Immune Deficiencies

CINCINNATI, Ohio (April 16, 2014) – BioRx, a national specialty pharmacy provider, announced today the expansion of its BioFeedback reporting program. Originally launched in September 2013 for autoimmune-related neuromuscular disorders, the program now offers a reporting package designed specifically for primary immune deficiency disease (PIDD). Similar to autoimmune disorders, BioFeedback for immune deficiencies tracks individual health outcomes that help measure a patient’s response to treatment with immunoglobulin (IgG) therapy.

Read the rest of this entry »

BioRx Introduces Smartphone App for Tracking Hemophilia Healthcare Information

The first hemophilia app developed by a specialty pharmacy.

CINCINNATI, Ohio (October 23, 2013) – BioRx, a national specialty pharmacy and infusion services provider, announced the launch of its industry’s first smartphone app designed for patients with hemophilia and related bleeding disorders. The app, called MyFactor, was developed and tested extensively by members of the hemophilia patient community. It was created to give patients and caregivers one place to easily monitor and manage their home treatment.

Read the rest of this entry »

BioRx Announces New Health Outcomes Reporting Program for Immunoglobulin Therapy

CINCINNATI, Ohio (September 9, 2013) – BioRx, a specialty infusion services provider, has introduced a health outcomes reporting program that provides routine clinical feedback on the use of home immunoglobulin (IgG) therapy in autoimmune-related neuromuscular disorders. The program, called BioFeedback, allows patients, physicians and insurance case managers to monitor drug utilization and administration records, hospital stays and ER visits, nursing notes, as well as view trended clinical metrics for some of the most common autoimmune disorders treated with IgG. Read the rest of this entry »

BioRx is featured in the Spring 2013 issue of Inside Healthcare magazine

BioRx is featured in the Spring 2013 issue of Inside Healthcare magazine

BioRx Introduces National Physical Therapy Program for Patients with Hemophilia

CINCINNATI, Ohio (February 19, 2013) – BioRx announced today the launch of a new physical therapy program to help patients, physicians, physical therapists, and health insurers manage the complications and costs of hemophilia-related joint damage. The program, called REBUILD, supports a patient’s physical therapy program at the local level.

Read the rest of this entry »

BioRx Receives Distribution Rights to Zemaira® [alpha-1 proteinase inhibitor (human)]

Cincinnati, Ohio  (October 29, 2012) - BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira® [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema. Read the rest of this entry »

BioRx is ranked #4 by Modern Healthcare among the “Healthcare’s Hottest Companies”

September 29, 2012 – BioRx is ranked #4 by Modern Healthcare among the “Healthcare’s Hottest Companies.”

BioRx Receives Limited Distribution Rights to Corifact® for the Treatment of Congenital Factor XIII Deficiency

Cincinnati, Ohio (July 11, 2012) — BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Corifact® [Factor XIII Concentrate (Human)], manufactured by CSL Behring. Corifact is the only FDA-approved treatment for congenital Factor XIII (FXIII) deficiency, reported to be one of the rarest bleeding disorders in the world. Read the rest of this entry »

BioRx Acquires Coagulife Pharmacy

Cincinnati, Ohio (July 9, 2012) — BioRx announced today that it has acquired Coagulife Pharmacy, a specialized provider of clotting factor medications and supplies for the treatment of hemophilia and related bleeding disorders. Read the rest of this entry »

BioRx Affirms Strong Supply of C1 Esterase Inhibitor Product

Cincinnati, Ohio (May 9, 2012) — In response to reports of a shortage of one C1 esterase inhibitor (C1-INH) product on the market, BioRx affirmed today that its supply of Berinert® (C1 esterase inhibitor, human) remains strong and can immediately accommodate increased demand. Read the rest of this entry »

 

Privacy Policy Website maintained by Infitech Web Design Services. Copyright 2009: BioRx. All Rights Reserved.